REG - AstraZeneca PLC - Director Declaration

AstraZenecaAnnouncement

16/07/2020 07:00

RNS Number : 1169T
  
AstraZeneca PLC
  
16 July 2020
  
 

16 July 2020 07:00 BST
 
 
Director Declaration 
 
AstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed as an independent Non-Executive Director of CSL Limited (ASX:CSL; USOTC:CSLLY), to be effective from 19 August 2020.
 
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
RDNXELFFBDLZBBX